A functional variant in the peroxisome proliferator-activated receptor γ2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians

被引:71
|
作者
Muller, YL
Bogardus, C
Beamer, BA
Shuldiner, AR
Baier, LJ
机构
[1] NIDDK, Clin Diabet & Nutr Sect, NIH, Phoenix, AZ 85016 USA
[2] NIDDK, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ 85016 USA
[3] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[4] Univ Maryland, Dept Med, Baltimore, MD 21201 USA
关键词
D O I
10.2337/diabetes.52.7.1864
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peroxisome proliferator-activated receptor gamma (PPARgamma)-2 is a member of the nuclear hormone receptor superfamily that is expressed predominantly in adipocytes and is thought to have a role in energy homeostasis, adipogenesis, and insulin sensitivity. A functional single nucleotide polymorphism (SNP) that predicts a proline to alanine substitution (Pro12Ala) within the coding region of this gene has previously been associated with obesity and type 2 diabetes in several populations. In this study, we identified several novel SNPs in the promoter region of PPARgamma2 and genotyped them, along with the previously identified Pro12A1a SNP. In 241 nondiabetic Pima subjects, the Pro12A1a was associated with whole-body insulin action (P = 0.05), hepatic insulin action (P = 0.03), and fasting plasma insulin concentrations (P = 0.01). One of the promoter SNPs positioned within a putative E2 box was in high linkage disequilibrium (\D'\ = 0.98) with the Pro12Ala. This promoter SNP was similarly associated with whole-body insulin action (P = 0.04) and hepatic insulin action (P = 0.05), but not fasting plasma insulin concentrations. Functional studies in transfected 3T3-L1 cells demonstrated that this single base substitution in the putative E2 box significantly altered transcriptional activity from a luciferase reporter construct. These data indicate that this promoter SNP, via its effect on PPARgamma2 expression, may also have functional consequences on PPARgamma2-activated pathways, and perhaps both the promoter SNIP and the Pro12Ala contribute to PPARgamma2-related phenotypes.
引用
收藏
页码:1864 / 1871
页数:8
相关论文
共 50 条
  • [31] MicroRNA-34a and promoter methylation contribute to peroxisome proliferator-activated receptor gamma gene expression in patients with type 2 diabetes
    Moghadasi, Mona
    Taherimoghaddam, Mozhgan
    Babaeenezhad, Esmaeel
    Birjandi, Mehdi
    Kaviani, Mozhgan
    Sarabi, Mostafa Moradi
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (10)
  • [32] Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter
    Girnun, GD
    Domann, FE
    Moore, SA
    Robbins, MEC
    MOLECULAR ENDOCRINOLOGY, 2002, 16 (12) : 2793 - 2801
  • [33] Genetic Variation in the Peroxisome Proliferator-Activated Receptor (PPAR) and Peroxisome Proliferator-Activated Receptor Gamma Co-activator 1 (PGC1) Gene Families and Type 2 Diabetes
    Villegas, Raquel
    Williams, Scott M.
    Gao, Yu-Tang
    Long, Jirong
    Shi, Jiajun
    Cai, Hui
    Li, Honglan
    Chen, Ching-Chu
    Tai, E. Shyong
    Hu, Frank
    Cai, Qiuyin
    Zheng, Wei
    Shu, Xiao-Ou
    ANNALS OF HUMAN GENETICS, 2014, 78 (01) : 23 - 32
  • [34] The peroxisome proliferator-activated receptor-γ2 P12A polymorphism and type 2 diabetes in an Arab population
    Wakil, SM
    Al-Rubeaan, K
    Alsmadi, O
    Imtiaz, F
    Carroll, P
    Rajab, M
    Al-Katari, S
    Al-Katari, M
    Meyer, BF
    DIABETES CARE, 2006, 29 (01) : 171 - 172
  • [35] Peroxisome proliferator-activated receptor gamma coactivator 1 alpha promoter polymorphisms are associated with early-onset type 2 diabetes mellitus in the Korean population
    J. H. Kim
    H. D. Shin
    B. L. Park
    Y. M. Cho
    S. Y. Kim
    H. K. Lee
    K. S. Park
    Diabetologia, 2005, 48 : 1323 - 1330
  • [36] Peroxisome proliferator-activated receptor gamma coactivator 1 alpha promoter polymorphisms are associated with early-onset type 2 diabetes mellitus in the Korean population
    Kim, JH
    Shin, HD
    Park, BL
    Cho, YM
    Kim, SY
    Lee, HK
    Park, KS
    DIABETOLOGIA, 2005, 48 (07) : 1323 - 1330
  • [37] Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver:: insights from models of obesity and type 2 diabetes
    Boelsterli, UA
    Bedoucha, M
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (01) : 1 - 10
  • [38] Inhibition of the actions of peroxisome proliferator-activated receptor a on obesity by estrogen
    Jeong, Sunhyo
    Yoon, Michung
    OBESITY, 2007, 15 (06) : 1430 - 1440
  • [39] Variants of uncoupling protein-2 gene and obesity:: interaction with peroxisome proliferator-activated receptorγ2
    Mancini, FP
    Sabatino, L
    Colantuoni, V
    Pasanisi, F
    Finelli, C
    Contaldo, F
    Masulli, M
    Riccardi, G
    Vaccaro, O
    CLINICAL ENDOCRINOLOGY, 2003, 59 (06) : 817 - 822
  • [40] Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes
    Erdmann, Erland
    Califf, Robert
    Gerstein, Hertzel C.
    Malmberg, Klas
    Ruilope, Luis
    Schwartz, Gregory G.
    Wedel, Hans
    Volz, Dietmar
    Ditmarsch, Marc
    Svensson, Anders
    Bengus, Monica
    AMERICAN HEART JOURNAL, 2015, 170 (01) : 117 - 122